Savara Inc. (SVRA)
NASDAQ: SVRA
· Real-Time Price · USD
2.44
0.06 (2.52%)
At close: Jun 06, 2025, 3:59 PM
2.44
0.21%
After-hours: Jun 06, 2025, 04:37 PM EDT
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
The company is headquartered in Austin, Texas.
Savara Inc.

Country | United States |
IPO Date | Apr 28, 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 59 |
CEO | Matthew Pauls J.D., M.B.A. |
Contact Details
Address: Building III Langhorne, Texas United States | |
Website | https://www.savarapharma.com |
Stock Details
Ticker Symbol | SVRA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001160308 |
CUSIP Number | 805111101 |
ISIN Number | US8051111016 |
Employer ID | 84-1318182 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Matthew Pauls J.D., M.B.A. | Chairman & Chief Executive Officer |
David L. Lowrance CPA | Chief Financial Officer, Chief Administrative Officer & Secretary |
Kate McCabe J.D. | Chief Legal Officer |
Robert Matthew Lutz M.B.A. | Chief Operating Officer |
Anne Erickson | Chief Business Officer |
Brian Maurer | Head of Clinical Operations |
Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs |
Dr. Brian Robinson M.D. | Executive Vice President of Global Medical Affairs |
Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer |
Dr. Yasmine Wasfi M.D., Ph.D. | Executive Vice President and Head of Clinical Development & Clinical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 02, 2025 | 4 | Filing |
May 27, 2025 | 8-K | Current Report |
May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 13, 2025 | 10-Q | Quarterly Report |
Apr 25, 2025 | ARS | Filing |
Apr 25, 2025 | DEFA14A | Filing |
Apr 25, 2025 | DEF 14A | Filing |
Apr 25, 2025 | 10-K/A | [Amend] Annual Report |
Apr 01, 2025 | 4 | Filing |
Mar 31, 2025 | 8-K | Current Report |